Cargando…

High Complete Response Rate in Patients With Metastatic Renal Cell Carcinoma Receiving Autologous Cytokine-Induced Killer Cell Therapy Plus Anti-Programmed Death-1 Agent: A Single-Center Study

BACKGROUND AND OBJECTIVE: The results of the CheckMate 025 trial established the status of nivolumab in the second-line treatment of metastatic renal cell carcinoma (mRCC), with an objective response rate (ORR) of 25% and a complete response (CR) rate of 1%. Thus, the efficacy of anti-programmed dea...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhao, Lingdi, Li, Tiepeng, Song, Yongping, Yang, Yonghao, Ma, Baozhen, Zhang, Yong, Shang, Yiman, Xu, Benling, Guo, Jindong, Qin, Peng, Han, Lu, Fu, Xiaomin, Lin, Hongwei, Liu, Liang, Ren, Xiubao, Wang, Zibing, Gao, Quanli
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8764153/ https://www.ncbi.nlm.nih.gov/pubmed/35058923 http://dx.doi.org/10.3389/fimmu.2021.779248

Ejemplares similares

Sintilimab maintenance therapy post first-line cytokine-induced killer cells plus chemotherapy for extensive-stage small cell lung cancer
por: Ma, Baozhen, et al.
Publicado: (2022)

Autologous cytokine-induced killer cell transfusion increases overall survival in advanced pancreatic cancer
por: Wang, Zibing, et al.
Publicado: (2016)

Clinical effects of autologous cytokine-induced killer cell-based immunotherapy in the treatment of endometrial cancer: a case report and literature review
por: Zhang, Yong, et al.
Publicado: (2017)

Axitinib Reverses Resistance to Anti-Programmed Cell Death-1 Therapy in a Patient With Renal Cell Carcinoma
por: Yang, Yonghao, et al.
Publicado: (2021)

Chemotherapy Reverses Anti-PD-1 Resistance in One Patient With Advanced Non-small Lung Cell Cancer
por: Zhao, Lingdi, et al.
Publicado: (2020)

The Sequence of Chemotherapy and Toripalimab Might Influence the Efficacy of Neoadjuvant Chemoimmunotherapy in Locally Advanced Esophageal Squamous Cell Cancer—A Phase II Study
por: Xing, Wenqun, et al.
Publicado: (2021)

MDSC-decreasing chemotherapy increases the efficacy of cytokine-induced killer cell immunotherapy in metastatic renal cell carcinoma and pancreatic cancer
por: Wang, Zibing, et al.
Publicado: (2015)

Randomized, multicenter, open-label trial of autologous cytokine-induced killer cell immunotherapy plus chemotherapy for squamous non-small-cell lung cancer: NCT01631357
por: Liu, Liang, et al.
Publicado: (2020)

Factors Influencing the Efficacy of Anti-PD-1 Therapy in Chinese Patients with Advanced Melanoma
por: Zhao, Lingdi, et al.
Publicado: (2019)

Rapid Response of Advanced Squamous Non-Small Cell Lung Cancer with Thrombocytopenia after First-Line Treatment with Pembrolizumab Plus Autologous Cytokine-Induced Killer Cells
por: Hui, Zhenzhen, et al.
Publicado: (2015)

Advanced Renal-Cell Carcinoma Pseudoprogression After Combined Immunotherapy: Case Report and Literature Review
por: Zhang, Xiaojie, et al.
Publicado: (2021)

Combination of Cytokine-Induced Killer Cells and Programmed Cell Death-1 Blockade Works Synergistically to Enhance Therapeutic Efficacy in Metastatic Renal Cell Carcinoma and Non-Small Cell Lung Cancer
por: Wang, Zibing, et al.
Publicado: (2018)

Case Report: Afatinib-Induced Interstitial Pneumonia: Experiences and Lessons From Two Patients
por: Liu, Xiao, et al.
Publicado: (2021)

Efficacy and Safety of Apatinib in Patients with Recurrent or Refractory Melanoma
por: Yuan, Shumin, et al.
Publicado: (2022)

Long-term survival of a patient with microsatellite-stable refractory colorectal cancer with regorafenib and PD-1 inhibitor sintilimab: a case report and review of literature
por: Zhang, Yong, et al.
Publicado: (2021)

Combination of Low-Dose Gemcitabine and PD-1 Inhibitors for Treatment in Patients With Advanced Malignancies
por: Huang, Hao, et al.
Publicado: (2022)

Toxic Epidermal Necrolysis-Like Reaction Following Combination Therapy With Camrelizumab and Apatinib for Advanced Gallbladder Carcinoma
por: Yang, Yonghao, et al.
Publicado: (2021)

A phase II, single-centre trial of neoadjuvant toripalimab plus chemotherapy in locally advanced esophageal squamous cell carcinoma
por: Xing, Wenqun, et al.
Publicado: (2020)

S-15 in combination of Akt inhibitor promotes the expansion of CD45RA(−)CCR7(+) tumor infiltrating lymphocytes with high cytotoxic potential and downregulating PD-1(+)Tim-3(+) cells as well as regulatory T cells
por: Xu, Benling, et al.
Publicado: (2019)

Somatic copy number alteration predicts clinical benefit of lung adenocarcinoma patients treated with cytokine-induced killer plus chemotherapy
por: Kou, Fan, et al.
Publicado: (2022)

Autologous cytokine‐induced killer (CIK) cells enhance the clinical response to PD‐1 blocking antibodies in patients with advanced non‐small cell lung cancer: A preliminary study
por: Han, Ying, et al.
Publicado: (2020)

Cytokine-Induced Killer Cells Modulates Resistance to Cisplatin in the A549/DDP Cell Line
por: Yang, Lili, et al.
Publicado: (2017)

Efficiency of Cytokine-Induced Killer Cells in Combination with Chemotherapy for Triple-Negative Breast Cancer
por: Li, Man, et al.
Publicado: (2018)

Autologous Cytokine-Induced Killer Cell Immunotherapy Enhances Chemotherapy Efficacy against Multidrug-Resistant Tuberculosis
por: Tang, Peijun, et al.
Publicado: (2022)

Improved Activation toward Primary Colorectal Cancer Cells by Antigen-Specific Targeting Autologous Cytokine-Induced Killer Cells
por: Schlimper, Claudia, et al.
Publicado: (2012)

Phase III randomized trial of autologous cytokine-induced killer cell immunotherapy for newly diagnosed glioblastoma in korea
por: Kong, Doo-Sik, et al.
Publicado: (2016)

Cytokine-induced killer cells are type II natural killer T cells
por: Gütgemann, Stefan, et al.
Publicado: (2007)

Circulating and tumor-infiltrating Tim-3 in patients with colorectal cancer
por: Xu, Benling, et al.
Publicado: (2015)

Novel treatment strategy with autologous activated and expanded natural killer cells plus anti-myeloma drugs for multiple myeloma
por: Leivas, Alejandra, et al.
Publicado: (2016)

The prognostic landscape of genes and infiltrating immune cells in cytokine induced killer cell treated-lung squamous cell carcinoma and adenocarcinoma
por: Wang, Jian, et al.
Publicado: (2021)

Autologous hematopoietic stem cell infusion for sustained myelosuppression after BCMA–CAR-T therapy in patient with relapsed myeloma
por: Lin, Quande, et al.
Publicado: (2019)

Efficacy and safety of trastuzumab as maintenance or palliative therapy in advanced HER2-positive gastric cancer
por: Fu, Xiaomin, et al.
Publicado: (2018)

Autologous Tumor Lysate-Pulsed Dendritic Cell Immunotherapy with Cytokine-Induced Killer Cells Improves Survival in Gastric and Colorectal Cancer Patients
por: Gao, Daiqing, et al.
Publicado: (2014)

Cytokine-induced killer cell/dendritic cell combined with cytokine-induced killer cell immunotherapy for treating advanced gastrointestinal cancer
por: Du, Hansong, et al.
Publicado: (2020)

Characterization of the killer cell generated in the autologous mixed leukocyte reaction
Publicado: (1983)

Cytokine-induced killer cells/natural killer cells combined with anti-GD2 monoclonal antibody increase cell death rate in neuroblastoma SK-N-SH cells
por: Zhang, Chi, et al.
Publicado: (2019)

Autologous transplantation of cytokine-induced killer cells as an adjuvant therapy for hepatocellular carcinoma in Asia: an update meta-analysis and systematic review
por: Cai, Xiu-Rong, et al.
Publicado: (2017)

FOLFOX regimen plus dendritic cells–cytokine-induced killer cells immunotherapy for the treatment of colorectal cancer: a meta-analysis
por: Liu, Yan, et al.
Publicado: (2017)

Cytokine-induced killer cells/dendritic cells and cytokine-induced killer cells immunotherapy for the treatment of esophageal cancer: A meta-analysis
por: Yuan, Xin, et al.
Publicado: (2021)

Autologous Cytokine-Induced Killer Cell Immunotherapy for Patients with High-Risk Diffuse Large B Cell Lymphoma After the First Complete Remission
por: Zhou, Min, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_qa420c2emk5q29s0moq5cng05e